MLN 3701
Alternative Names: AVE 1701; Inflammation therapy - sanofi-aventis/Millennium; MLN3701Latest Information Update: 17 Mar 2009
At a glance
- Originator Millennium Pharmaceuticals; sanofi-aventis
- Developer Millennium
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action CCR1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 17 Mar 2009 Discontinued - Phase-I for Inflammation in USA (PO)
- 17 Mar 2009 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
- 14 May 2008 Takeda acquires Millennium